Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective
出版年份 2013 全文链接
标题
Malignant astrocytomas of elderly patients lack favorable molecular markers: an analysis of the NOA-08 study collective
作者
关键词
-
出版物
NEURO-ONCOLOGY
Volume 15, Issue 8, Pages 1017-1026
出版商
Oxford University Press (OUP)
发表日期
2013-04-18
DOI
10.1093/neuonc/not043
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- MGMT methylation analysis of glioblastoma on the Infinium methylation BeadChip identifies two distinct CpG regions associated with gene silencing and outcome, yielding a prediction model for comparisons across datasets, tumor grades, and CIMP-status
- (2012) Pierre Bady et al. ACTA NEUROPATHOLOGICA
- Hotspot Mutations in H3F3A and IDH1 Define Distinct Epigenetic and Biological Subgroups of Glioblastoma
- (2012) Dominik Sturm et al. CANCER CELL
- Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial
- (2012) Wolfgang Wick et al. LANCET ONCOLOGY
- IDH mutation impairs histone demethylation and results in a block to cell differentiation
- (2012) Chao Lu et al. NATURE
- IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype
- (2012) Sevin Turcan et al. NATURE
- Driver mutations in histone H3.3 and chromatin remodelling genes in paediatric glioblastoma
- (2012) Jeremy Schwartzentruber et al. NATURE
- Geriatric neuro-oncology
- (2011) Michael Weller et al. CURRENT OPINION IN NEUROLOGY
- Characterization of Molecular Genetic Alterations in GBMs Highlights a Distinctive Molecular Profile in Young Adults
- (2011) Prerana Jha et al. DIAGNOSTIC MOLECULAR PATHOLOGY
- Alkylpurine–DNA–N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients
- (2011) Sameer Agnihotri et al. JOURNAL OF CLINICAL INVESTIGATION
- Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial
- (2011) Jaime Gállego Pérez-Larraya et al. JOURNAL OF CLINICAL ONCOLOGY
- Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas
- (2010) Christian Hartmann et al. ACTA NEUROPATHOLOGICA
- Comparison of Beta-value and M-value methods for quantifying methylation levels by microarray analysis
- (2010) Pan Du et al. BMC BIOINFORMATICS
- Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
- (2010) Houtan Noushmehr et al. CANCER CELL
- Radiation Dose–Volume Effects in the Brain
- (2010) Yaacov Richard Lawrence et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Molecular Predictors of Progression-Free and Overall Survival in Patients With Newly Diagnosed Glioblastoma: A Prospective Translational Study of the German Glioma Network
- (2009) Michael Weller et al. JOURNAL OF CLINICAL ONCOLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Aging and Environmental Exposures Alter Tissue-Specific DNA Methylation Dependent upon CpG Island Context
- (2009) Brock C. Christensen et al. PLoS Genetics
- Patterns of care in elderly glioblastoma patients
- (2008) Fabio M. Iwamoto et al. ANNALS OF NEUROLOGY
- Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme
- (2008) Angelique E. Sijben et al. JOURNAL OF NEURO-ONCOLOGY
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
- An Integrated Genomic Analysis of Human Glioblastoma Multiforme
- (2008) D. W. Parsons et al. SCIENCE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started